Post-effective amendment to a registration statement that is not immediately effective upon filing

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY - P3 Health Partners Inc. - USD ($)
Common Stock
Common Class A
Common Stock
Common Class V
Additional Paid-in Capital
Accumulated Deficit
Redeemable Non-Controlling Interests
Total
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 03, 2021 $ 4,158 $ 19,655 $ 312,945,752 [1] $ (29,336,924)   $ 283,632,641
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 03, 2021 41,578,890 196,553,523        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Loss       (10,081,200)   (10,081,200)
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 31, 2021 $ 4,158 $ 19,655 312,945,752 [1] (39,418,124)   273,551,441
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 31, 2021 41,578,890 196,553,523        
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         $ 4,635,142  
Net Loss         (47,856,729)  
Ending Balance at Dec. 31, 2021         1,790,617,285 1,790,617,285
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Vesting of stock compensation awards   $ 55       55
Vesting of stock compensation awards (in shares)   549,822        
Net Loss       (10,577,504)   (10,577,504)
STOCKHOLDERS' EQUITY (DEFICIT) at Mar. 31, 2022 $ 4,158 $ 19,710 312,945,752 (49,995,628)   262,973,992
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Mar. 31, 2022 41,578,890 197,103,345        
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         11,711,427  
Net Loss         (50,212,750)  
Ending Balance at Mar. 31, 2022         1,752,115,962  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Vesting of stock compensation awards   $ 432       432
Vesting of stock compensation awards (in shares)   4,319,964        
Net Loss       (154,349,949)   (154,349,949)
STOCKHOLDERS' EQUITY (DEFICIT) at Jun. 30, 2022 $ 4,158 $ 20,142 $ 312,945,752 $ (204,345,577)   108,624,475
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Jun. 30, 2022 41,578,890 201,423,309        
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         3,715,553  
Net Loss         (748,755,990)  
Ending Balance at Jun. 30, 2022         $ 1,007,075,525 $ 1,007,075,525
[1] Included in the opening balance are transactions completed in connection with the Business Combinations, including the PIPE investment of $195.3 million (net of issuance costs), the equity consideration to P3 shareholders of $80.3 million, and the trust proceeds (net of redemptions) of $37.4 million.